Ashiya, Japan

Tatsuya Kon

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 104(Granted Patents)


Company Filing History:


Years Active: 1985-1993

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Tatsuya Kon: Innovator in Medicinal Chemistry

Introduction

Tatsuya Kon is a prominent inventor based in Ashiya, Japan, known for his significant contributions to medicinal chemistry. With a total of eight patents to his name, he has made remarkable advancements in the treatment of cerebral insufficiency diseases.

Latest Patents

His latest patents include a novel medicament for treating cerebral insufficiency diseases, which comprises an active ingredient with a specific chemical formula. This innovative compound aims to improve cerebral function and offers potential therapeutic benefits. Additionally, he has developed 6-amino-1,4-hexahydro-1H-diazepine derivatives and indazole-3-carboxylic acid derivatives, which serve as potent antagonists of the serotonin 3 (5-HT3) receptor. These compounds are also useful as intermediates in the production of final product compounds.

Career Highlights

Tatsuya Kon is associated with Dainippon Pharmaceutical Company, Limited, where he has been instrumental in advancing pharmaceutical research and development. His work has focused on creating effective treatments for neurological conditions, showcasing his dedication to improving patient outcomes.

Collaborations

Throughout his career, Tatsuya has collaborated with notable colleagues, including Katsuhiko Hino and Tadahiko Karasawa. These partnerships have fostered a collaborative environment that enhances innovation and research in the field of medicinal chemistry.

Conclusion

Tatsuya Kon's contributions to medicinal chemistry and his innovative patents reflect his commitment to advancing healthcare solutions. His work continues to impact the treatment of cerebral insufficiency diseases, showcasing the importance of research and development in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…